Greenbrook

Greenbrook

Provides innovative, non-invasive treatments like Transcranial Magnetic Stimulation (TMS) and Spravato® for depression and OCD.

  • Edit
Get premium to view all results
DateInvestorsAmountRound
-investor

€0.0

round
N/A

€0.0

round
N/A

€0.0

round
N/A

€0.0

round
investor

€0.0

round
N/A

€0.0

round
N/A

€0.0

round
investor

€0.0

round
investor

€0.0

round
investor

€0.0

round
investor

€0.0

round
investor

€0.0

round
*

N/A

Acquisition
Total Funding000k

Financials

Estimates*

Get premium to view all results
Edit
Revenues, earnings & profits over time
USD2017201820192020202120222023
Revenues0000000000000000000000000000
% growth-54 %68 %21 %21 %32 %7 %
EBITDA0000000000000000000000000000
% EBITDA margin(14 %)(21 %)(18 %)(26 %)(31 %)(28 %)(39 %)
Profit0000000000000000000000000000
% profit margin(17 %)(23 %)(45 %)(69 %)(47 %)(89 %)(66 %)
EV0000000000000000000000000000
EV / revenue00.0x00.0x00.0x00.0x00.0x00.0x00.0x
EV / EBITDA00.0x00.0x00.0x00.0x00.0x00.0x00.0x
R&D budget0000000000000000000000000000
R&D % of revenue2 %2 %4 %1 %2 %1 %-

Source: Company filings or news article

More about Greenbrook
Edit

Greenbrook TMS NeuroHealth is the nation’s leading provider of Transcranial Magnetic Stimulation (TMS) therapy, an FDA-cleared, non-invasive therapy for the treatment of Major Depressive Disorder and Obsessive Compulsive Disorder. Since 2011, we’ve provided more than 320,000 life-changing TMS treatments to over 9,000 patients. Learn more at greenbrooktms.com

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo

Investments by Greenbrook

Edit
Achieve TMS East and Central
ACQUISITION by Greenbrook Sep 2021
Success TMS
ACQUISITION by Greenbrook May 2022